Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049439 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00049439 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 54 participants.
The verdict
NCT00049439, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients who have AIDS-related non-Hodgkin's lymphoma.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG lomustine
- DRUG procarbazine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 1998-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049439
The ClinicalTrials.gov registry entry for NCT00049439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00049439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049439 about?
NCT00049439 is a clinical study titled "Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining lomustine, etoposide, cyclophosphamide, and procarbazine ...
What is the current status of trial NCT00049439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 1998-03. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00049439?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), lomustine (DRUG), procarbazine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00049439?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.